Citius Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Citius Pharmaceuticals generated cash of -$24,250,414, which is less than the previous year. Cash used in financing activities reached the amount of $120,470,550 last year. Net change in cash is therefore $56,213,198.
Cash Flow
| 2012 | -20.32K | 0 | 20.24K |
|---|---|---|---|
| 2013 | -20.60K | 0 | 20.46K |
| 2014 | 0 | 1.55M | 0 |
| 2015 | -2.38M | 0 | 1.50M |
| 2016 | -5.90M | 255.74K | 5.26M |
| 2017 | -7.97M | -2.12K | 10.88M |
| 2018 | -11.31M | 0 | 17.29M |
| 2019 | -12.43M | 0 | 11.14M |
| 2020 | -16.93M | -1.83K | 22.89M |
| 2021 | -24.25M | -40.00M | 120.47M |
CTXRW Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.85M | 7.89M | 9.18M | 3.20M | 294.35K | 676.13K | 1.55M | 0 | 135 | 212 |
Operating activities | ||||||||||
Net income | -23.05M | -17.54M | -15.56M | -12.53M | -8.29M | -8.29M | -2.90M | 0 | -31.36K | -22.00K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 164.86K | 152.36K | 893 | 1.75K | 1.34K | 1.34K | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 1.45M | 803.26K | 715.98K | 779.70K | 986.62K | 732.15K | 486.27K | 0 | 0 | 0 |
| Deferred income tax benefit | 1.45M | 803.26K | 715.98K | 779.70K | 986.62K | 732.15K | 486.27K | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -579.14K | -857.30K | 1.14M | 971.01K | -306.72K | 105.23K | 452.98K | 0 | 11.47K | -906 |
Cash generated by operating activities | -24.25M | -16.93M | -12.43M | -11.31M | -7.97M | -5.90M | -2.38M | 0 | -20.60K | -20.32K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -40.00M | -1.83K | 0 | 0 | -2.12K | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 255.74K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -40.00M | -1.83K | 0 | 0 | -2.12K | 255.74K | 0 | 1.55M | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 89.43M | 15.57M | 11.12M | 16.17M | 6.67M | 5.42M | 1.50M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.55M | 0 | 0 |
Repayments of term debt | -172.97K | 0 | 0 | 0 | 0 | -600K | 0 | 0 | -30.14K | 0 |
Cash used in financing activities | 120.47M | 22.89M | 11.14M | 17.29M | 10.88M | 5.26M | 1.50M | 0 | 20.46K | 20.24K |
Net Change In Cash | 56.21M | 5.96M | -1.29M | 5.97M | 2.90M | -381.78K | -875.92K | 1.55M | -135 | -77 |
Cash at end of period | 70.07M | 13.85M | 7.89M | 9.18M | 3.20M | 294.35K | 676.13K | 1.55M | 0 | 135 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |